Bpifrance Epic Sells 2,076,990 Shares of DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A. (NASDAQ:DBVT) major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bpifrance Epic also recently made the following trade(s):

• On Thursday, December 18th, Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock. The stock was sold at an average price of $4.19, for a total transaction of $5,413,911.57.

DBV Technologies Trading Up 5.8%

DBV Technologies stock opened at $22.76 on Friday. DBV Technologies S.A. has a 1-year low of $2.92 and a 1-year high of $26.18. The company has a fifty day simple moving average of $15.38 and a 200 day simple moving average of $11.86. The company has a market cap of $914.04 million, a P/E ratio of -4.40 and a beta of -1.10.

Key DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: Phase‑III win in peanut allergy improves commercial/clinical outlook — a Bioworld report says DBV’s VIT® program delivered a positive Phase III result, a material de‑risking event for a lead program that can drive future revenue and re‑rating. Vitesse finesse pays off: DBV wins in peanut allergy phase III
• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts, signaling stronger long‑term profitability expectations (FY2027–FY2029 upgrades). That upward revision likely helped investor sentiment and price momentum. HC Wainwright Expects Stronger Earnings for DBV Technologies
• Positive Sentiment: Additional bullish analyst notes and coverage changes — the stock was reported to hit a new 1‑year high after analyst upgrades, and coverage consensus sits around a “Moderate Buy,” with at least one firm (Citizens JMP) forecasting strong price appreciation. Those actions typically boost retail/institutional interest. DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade
• Neutral Sentiment: Market consensus EPS remains deeply negative for the current year (consensus ~($7.05) EPS), so while upgrades are meaningful, the company is still transitioning from loss‑making to profitable — investors should watch upcoming milestones and cash runway closely.
• Negative Sentiment: Major shareholder Bpifrance Epic sold large blocks of stock on Dec 17–18 (combined ~3.37M shares sold across two days, materially reducing its stake). Large insider/major‑holder selling can pressure the stock and signal liquidity‑driven exits even when fundamentals improve. SEC filing: Bpifrance Epic Insider Sales SEC Filing
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (worse near‑term profitability view), a reminder that boutique analysts still see near‑term execution and cash burn risk — this can cap upside until revenue/profitability is proven.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the company. New York State Common Retirement Fund acquired a new stake in DBV Technologies during the 3rd quarter worth approximately $34,000. Two Sigma Investments LP bought a new position in DBV Technologies during the 3rd quarter worth $167,000. Citadel Advisors LLC acquired a new stake in shares of DBV Technologies during the third quarter worth $220,000. DLD Asset Management LP bought a new stake in shares of DBV Technologies in the third quarter valued at about $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of DBV Technologies in the second quarter valued at about $340,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Citizens Jmp lifted their price target on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, HC Wainwright set a $40.00 price objective on DBV Technologies in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $35.38.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.